Massive Bio Completes SOC 2 Type 1 Certification for Its AI Enabled Oncology Technology Platforms Including Patient Centric Clinical Trial Matching and Enrollment Services

NEW YORK--(BUSINESS WIRE)--Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment, today announced it has successfully achieved Type 1 Service Organization Control (SOC 2 ®) compliance examination for its flagship digital health platforms. The audit was performed by Control Logics, who have “implemented risk management methodologies and performed security assessments at over 200 companies located in North America, Europe and Asia” (Source: https://control-logics.com/). As more healthcare companies trust cloud service providers, it is important to ensure security of healthcare data. By achieving Type 1 certification, an independent third party has validated the design of Massive Bio’s controls relevant to its information security practices, policies, procedures, and operations meet the rigorous SOC 2 standards for security, availability, processing integrity, confidentiality, and privacy.

Developed by the American Institute of Certified Public Accountants (AICPA), SOC 2 ® certification is widely recognized as a gold standard for data security and requires companies to establish and follow strict information security policies and procedures. The goal of the SOC 2 Type 1 audit was to ensure Massive Bio’s operational controls meet the stringent standards of “security, availability, processing integrity, confidentiality, and privacy of a system” (Source: https://control-logics.com/soc-2-report/). The services reviewed by Control Logics for the report included Massive Bio’s enterprise solutions (https://massivebio.com/business-capabilities): the Clinical Trial Matching System (CTMS), Virtual Tumor Board (VTB), Real-World Insights and Evidence (RWE).

“As a cutting-edge oncology technology platform, Massive Bio’s SOC 2 Type 1 certification demonstrates our strong commitment to data security and confidential information of our customers. Given that we have developed the world’s first detailed virtual oncology pre-screening outside the trial site and get into the details of clinical and genomic information, we are laser focused on protecting and securing the valuable healthcare data,” said Selin Kurnaz, PhD, CEO of Massive Bio.

Massive Bio is proud to achieve this certification as the digital landscape for EMR (Electronic Medical Records) and PHI (Protected Health Information) grows exponentially. Customers can now be assured their private information will remain confidential throughout Massive Bio’s services. Massive Bio’s CTO Cagatay Culcuoglu stated that “Our services and majority of patient data are stored and delivered virtually, proving why a SOC 2 ® Type 1 certification is so valuable for Massive Bio”.

In addition to SOC 2 ® compliance, Massive Bio is making several enhancements to its infrastructure by adding new layers of redundancy and increasing monitoring coverage of its platform.

About Massive Bio

Massive Bio https://massivebio.com/ is an oncology dedicated company that controls patient enrollment value chain – from patient identification through enrollment. AI-driven platform connecting cancer patients and their community oncologists to bio-pharmaceutical clinical trials yielding profound improvement in access and match rates leading to faster drug development timelines and creating novel oncology data ecosystem for improved protocol design and real-world insights. AI pre-screening technology for 11,000 clinical trials with proprietary ontology of 50,000 oncology elements.